<DOC>
	<DOCNO>NCT00974766</DOCNO>
	<brief_summary>Allergic bronchopulmonary aspergillosis ( ABPA ) pulmonary disorder cause complex hypersensitivity response antigen release fungus Aspergillus fumigatus . Oral corticosteroid currently treatment choice ABPA associate bronchial asthma . They suppress immune hyperfunction also anti-inflammatory . However , data guide dose duration glucocorticoid different regimen glucocorticoid use literature . The disorder highly prevalent India . The investigator previously report experience screen stable outpatient bronchial asthma acute severe asthma ABPA . The investigator also recently report prognostic factor associate clinical outcome patient ABPA . The aim prospective randomize control trial ( RCT ) evaluate efficacy safety two different glucocorticoid dose protocols patient ABPA .</brief_summary>
	<brief_title>Trial Efficacy Safety Two Different Glucocorticoid Dose Regimens Allergic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Diagnosis ABPA Presence follow three criterion : 1. immediate cutaneous hyperreactivity aspergillus skin test 2. elevate total IgE level &gt; 1000 IU/mL 3 . A fumigatus specific IgE level &gt; 0.35 kU/L , AND , Presence two follow criterion : 1. presence serum precipitate antibody A fumigatus 2. fix transient radiographic pulmonary opacity 3. absolute eosinophil count &gt; 1000/ÂµL 4. central bronchiectasis HRCT If take glucocorticoid three week precede six month Failure give inform consent Enrollment another trial ABPA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>bronchial asthma</keyword>
	<keyword>allergic bronchopulmonary aspergillosis</keyword>
</DOC>